Biomaterial Database

A new contrast agent for oral cholecystography: iopronic acid (Oravue). 1978

N F Pizzolato, and J P Arcomano, and A E Baum

In a preliminary study to determine the safety and minimal effective dose in patients with impaired hepatic function, the cholecystographic agent iopronic acid (Oravue, research contrast material from Squibb) was well tolerated in single oral doses of 1.5, 3.0, 4.5, or 6.0 g. None of the patients experienced clinical adverse reactions. The radiologic results were generally poor, as anticipated for patients with total serum bilirubin concentrations of 2.0-11.4 mg/100 ml. In a subsequent double-blind controlled study in patients without hapatic dysfunction, 4.5 g of iopronic acid or 3.0 g of iopanoic acid (Telepaque, Winthrop) was given to two groups of 90 patients each. Serial radiographs were obtained 13, 14, 15, and 16 hr after ingestion of the drug. Both drugs were highly effective cholecystographic agents, producing visualization in 88% of the patients. Although not statistically significant, a repeat dose was required for visualization in only 4% of the patients given iopronic acid compared to 9% of the patients given iopanoic acid. Visualization was nearly always observed on the first film obtained 13 hr after drug administration. The contrast agents were similar in terms of safety.

UI	MeSH Term	Description	Entries
D007462	Iodobenzenes	Any derivative of BENZENE that contains IODINE.
D007480	Iopanoic Acid	Radiopaque medium used as diagnostic aid.	Iodopanoic Acid,Cholevid,Iopagnost,Polognost,Telepaque,Acid, Iodopanoic,Acid, Iopanoic
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D002765	Cholecystography	Radiography of the gallbladder after ingestion of a contrast medium.	Cholecystographies
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D003287	Contrast Media	Substances used to allow enhanced visualization of tissues.	Radiopaque Media,Contrast Agent,Contrast Agents,Contrast Material,Contrast Materials,Radiocontrast Agent,Radiocontrast Agents,Radiocontrast Media,Agent, Contrast,Agent, Radiocontrast,Agents, Contrast,Agents, Radiocontrast,Material, Contrast,Materials, Contrast,Media, Contrast,Media, Radiocontrast,Media, Radiopaque
D004311	Double-Blind Method	A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.	Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004361	Drug Tolerance	Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL.	Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260	Female		Females